27256-91-3

Basic information

• Product Name: 4-hydrazinylpyridine hydrochloride
• Synonyms: 4-hydrazinylpyridine hydrochloride;4-hydrazinylpyridine dihydrochloride;Pyridine, 4-hydrazinyl-;pyridine, 4-hydrazino-;4-Hydrazinopyridine;4-hydrazinylpyridine;4-hydrazinopyridine(SALTDATA: HCl);4-Hydrazinopyridine (ForM: HCl)
• CAS NO: 27256-91-3
• Molecular Formula: C₅H₇N₃
• Molecular Weight: 109.13
• EINECS: -0
• Mol File: 27256-91-3.mol
• Article Data: 9

Chemical Properties

• Melting Point: 30 °C
• Boiling Point: 286.4 °C at 760 mmHg
• Flash Point: 127 °C
• Appearance: /
• Density: 1.222 g/cm³
• Vapor Pressure: 0.00265mmHg at 25°C
• Refractive Index: 1.657
• PKA: 8.24±0.26(Predicted)
• CAS DataBase Reference: 4-hydrazinylpyridine hydrochloride(CAS DataBase Reference)
• NIST Chemistry Reference: 4-hydrazinylpyridine hydrochloride(27256-91-3)
• EPA Substance Registry System: 4-hydrazinylpyridine hydrochloride(27256-91-3)

Safety Data

• Hazardous Substances Data: 27256-91-3(Hazardous Substances Data)

Usage

Uses

4-Hydrazinylpyridine is Hydrazonopyrrolidine derivative for use in preventing and/or treating disorders associated to Acinetobacter baumannii.

InChI:InChI=1/C5H7N3/c6-8-5-1-3-7-4-2-5/h1-4H,6H2,(H,7,8)

Upstream product

• 74129-11-6 4-bromopyridine hydrobromide salt 
• 7379-35-3 4-chlorpyridine hydrochloride 
• 7803-57-8 hydrazine hydrate 
• 20815-52-5 4-hydrazinopyridine hydrochloride 
• 302-01-2 hydrazine 
• 7647-01-0 hydrogenchloride 
• 26482-55-3 4-(nitroamino)pyridine 
• 626-61-9 4-Chloropyridine 

Downstream Products

• 210173-41-4 N-(3-phenyl-propylidene)-N'-pyridin-4-yl-hydrazine 
• 210173-44-7 N-[3-(4-methoxy-phenyl)-propylidene]-N'-pyridin-4-yl-hydrazine 
• 210173-47-0 N-[3-(3-methoxy-phenyl)-propylidene]-N'-pyridin-4-yl-hydrazine 
• 210173-40-3 N-{3-[4-(tert-butyl-dimethyl-silanyloxy)-3-methoxy-phenyl]-propylidene}-N'-pyridin-4-yl-hydrazine 
• 91396-98-4 4-(2-(2-hydroxybenzylidene)hydrazinyl)pyridine 
• 50356-97-3 4-(2-(2-methylbenzylidene)hydrazinyl)pyridine 
• 1215760-28-3 4-(2-(2-methoxybenzylidene)hydrazinyl)pyridine 
• 1443362-67-1 4-(5-(4-bromophenyl)-1H-pyrazol-1-yl)pyridine 
• 1056633-94-3 5-cyclohexyl-1-pyridin-4-yl-1,5-dihydro-pyrazolo[3,4-d]pyrimidin-4-one 

Relevant articles and documents

Synthesis, CYP 450 evaluation, and docking simulation of novel 4-aminopyridine and coumarin derivatives

Four series of novel compounds based on 4-aminopyridine, glatiramer acetate, pyrone, and coumarin backbones were sufficiently synthesized and identified by spectroscopic methods. CYP enzyme inhibition assays of five predominate human P450 isozymes indicate that all compounds, except for 4-hydrazide pyridine 1c, seem to be less toxic than 4-aminopyridine. Further investigation of the compounds using molecular docking experiments revealed different, the same, or stronger binding modes for most of the synthesized compounds, with both polar and hydrophobic interactions with the 1WDA and 1J95 receptors compared to benzoyl l-arginine amide and 4-aminopyridine, respectively. These results introduce the synthesized compounds as K+ channel blockers that could be considered for in vivo CNS disease studies.

The compound of the structural unit containing pyrazole

The invention discloses a compound containing a pyrazole structural unit. A structural general formula of the compound is shown as a formula I. Because that an electrophosphorescent material requires good film-forming performance and a high-efficiency phosphorescence material having short phosphorescence life, by aiming at enhancement of luminescence efficiency and luminescent device performance, the invention provides a series of electrophosphorescent materials of iridium or platinum complex having pyrazole group. The compound has excellent film forming ability and high luminescence efficiency, the raw material is easily available, the compound is simple to prepare, the total yield is high, the cost of phosphorescence material is greatly reduced, and the compound has important application value.

UREA COMPOUNDS USEFUL IN THE TREATMENT OF CANCER

Pyrazole urea compounds, pharmaceutical compositions which contain them and methods for treating cancer using them.